MML Investors Services
CRSP icon

MML Investors Services’s CRISPR Therapeutics CRSP Stock Holding History

MML Investors Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$508K Buy
9,316
+1,915
+26% +$101K ﹤0.01% 2462
2026
Q1 		$352K Sell
7,401
-27,360
-79% -$1.44M ﹤0.01% 2461
2025
Q4 		$1.82M Buy
34,761
+29,712
+588% +$1.78M ﹤0.01% 1427
2025
Q3 		$327K Buy
+5,049
New +$290K ﹤0.01% 2452
2024
Q3 		– Sell
-7,240
Closed -$391K – 2584
2024
Q2 		$391K Sell
7,240
-1,821
-20% -$105K ﹤0.01% 1932
2024
Q1 		$618K Sell
9,061
-2,950
-25% -$211K ﹤0.01% 1677
2023
Q4 		$752K Sell
12,011
-12,645
-51% -$699K ﹤0.01% 1523
2023
Q3 		$1.12M Buy
24,656
+3,930
+19% +$203K 0.01% 1165
2023
Q2 		$1.16M Buy
+20,726
New +$1.18M 0.01% 1162
2023
Q1 		– Sell
-15,090
Closed -$613K – 2118
2022
Q4 		$613K Buy
15,090
+1,729
+13% +$91.7K ﹤0.01% 1398
2022
Q3 		$873K Buy
13,361
+1,484
+12% +$108K 0.01% 1126
2022
Q2 		$722K Buy
11,877
+5,346
+82% +$314K 0.01% 1207
2022
Q1 		$410K Buy
6,531
+2,117
+48% +$133K ﹤0.01% 1561
2021
Q4 		$334K Sell
4,414
-1,046
-19% -$91.4K ﹤0.01% 1642
2021
Q3 		$611K Buy
5,460
+269
+5% +$33.8K ﹤0.01% 1250
2021
Q2 		$840K Buy
5,191
+1,175
+29% +$143K 0.01% 1073
2021
Q1 		$489K Sell
4,016
-172
-4% -$26K ﹤0.01% 1280
2020
Q4 		$641K Buy
+4,188
New +$495K 0.01% 1036

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MML Investors Services's CRSP Position: Q2 2026 in Review

MML Investors Services increased its CRISPR Therapeutics (CRSP) stake by 26% in Q2 2026, buying an estimated $101K and bringing the position to 9,316 shares worth $508K. The position accounts for ﹤0.01% of the portfolio, ranked #2462.

MML Investors Services first reported a position in CRSP in Q4 2020 and has held it in 18 quarters since. The position peaked at $1.82M in Q4 2025. 271 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • MML Investors Services held 9,316 shares of CRISPR Therapeutics worth $508K as of Q2 2026.
  • MML Investors Services bought 1,915 CRISPR Therapeutics shares in Q2 2026, an estimated $101K.
  • CRISPR Therapeutics made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #2462 holding.
  • MML Investors Services first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 18 quarters since.
  • MML Investors Services's CRISPR Therapeutics position peaked at $1.82M in Q4 2025.
  • 271 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.